On May 17, SMO company Prius landed on the Growth Enterprise Market with an initial IPO price of 46.8 yuan per share. As of noon, Prius rose to 76.55 yuan per share, an increase of 63.57%, with a total market value of nearly 4.6 billion yuan. After the issuance was completed, Price became the first SMO listed company listed on A-shares.
SMO (Site Management Organization) is a clinical trial site management organization dedicated to providing clinical trial relatedprofessional serviceA department that assists researchers and research institutions to undertake non-doctor-judgment-related transactional work in clinical trials, improves the quality and progress of clinical trials, and promotes the standardization process of clinical trials.
Prius was established in 2013, its main business is to provide domestic and foreign pharmaceutical companies,medical instrumentsProvide SMO services for the clinical research and development of the company and some health-related products.It has established good cooperative relations with more than 730 clinical trial institutions. So far, it has promoted more than 80 innovative drugs ormedical instrumentsProducts are listed at home and abroad.Major customers coveredMSD、Novo Nordisk、Bristol-Myers Squibb、Eli LillyBayer,AbbVieand other well-known multinational pharmaceutical companies.
The prospectus shows that the number of shares issued this time is 15 million shares, accounting for 25% of the total share capital after the issuance;new sharesIssue, no originalshareholderpublic offering.
According to preliminary calculations, Prius expects that the period from January to March 2022 will beOperating incomeAbout 118 million yuan to 132 million yuan, a year-on-year increase of 21.47% to 35.88%;net profitIt was 11 million to 13 million yuan, a year-on-year increase of 12.50% to 32.96%.
(Article source: Beijing News)